Oncology Pharmacy in Your Community - CAPhO

2007 | NOPS SPEAKER
DR. MARGOT BURNELL
Medical Oncologist, Saint John Regional Hospital
BIOGRAPHY
Dr. Margot Burnell is a medical oncologist practising in the Department of Oncology at the Saint John Regional Hospital in Saint John
New Brunswick. She obtained her medical degree from the University of Western Ontario and did her residency in Internal Medicine
and Medical Oncology at the University of Toronto. Upon completion she did a Fellowship in Medical Oncology at the Royal Marsden
Fulham Road London UK. She has been practicing in Saint John for 20 years and is actively involved in both clinical practice as well
as clinical research. She is currently a member of the NCIC-Breast Site Committee and the NCIC Clinical Trials Committee. She is a
Co-Principal Investigator of MA-21.
SYNOPSIS
ADVANCES IN THE TREATMENT OF BREAST CANCER: Saturday, October 27th, 15:35 - 16:35
RESULTS OF THE MA.21 STUDY
Objectives:
1. To review the background of adjuvant breast cancer chemotherapy .
2. To review the design and results of NCIC CTG MA21. A PHASE III ADJUVANT TRIAL OF SEQUENCED EC + FILGRAS-
TIM + EPOETIN ALFA FOLLOWED BY PACLITAXEL VERSUS SEQUENCED AC FOLLOWED BY PACLITAXEL VERSUS
CEF AS THERAPY FOR PREMENOPAUSAL WOMEN AND EARLY POSTMENOPAUSAL WOMEN WHO HAVE HAD
POTENTIALLY CURATIVE SURGERY FOR NODE POSITIVE OR HIGH RISK NODE NEGATIVE BREAST CANCER.
3. To discuss the management of side effects related to each of the chemotherapy regimens.
4. To provide an overview of clinical decision making in the adjuvant setting.
5. To discuss the clinical relevance of MA21.
PRESENTATION
Speaker handouts for this presentation will be available onsite.
NOPS — Oncology Pharmacy in Your Community, October 26-28, 2007
Page 92